DANA-FARBER CANCER INSTITUTE
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Geriatric Thoracic Surgery Ambulation Challenge
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT04630496
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
ABEMA Alone or in COMBO With MK-6482
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04627064
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT04620187
- Locations
- ๐บ๐ธ
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธMemorial Sloan Kettering Commack, Commack, New York, United States
๐บ๐ธMemorial Sloan Kettering Nassau, Uniondale, New York, United States
Axi-cel in CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT04608487
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBrigham and Women's Hospital, Boston, Massachusetts, United States
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT04584255
- Locations
- ๐บ๐ธ
Yale University Cancer Center, New Haven, Connecticut, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Copanlisib Plus Venetoclax in R/R DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT04572763
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธCity of Hope Cancer Center, Duarte, California, United States
๐บ๐ธSiteman Cancer Center at Washington University, Saint Louis, Missouri, United States
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 375
- Registration Number
- NCT04569747
- Locations
- ๐บ๐ธ
UNC Rex Cancer Center, Raleigh, North Carolina, United States
๐บ๐ธStamford Hospital, Stamford, Connecticut, United States
๐บ๐ธWinship Cancer Institute at Emory University Hospital Midtown, Atlanta, Georgia, United States
My Mindful Moments: A Mindfulness Meditation and Digital Art Activity
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT04557033
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Jump: MR Simulation For Radiation Therapy Master Protocol
- Conditions
- Interventions
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 86
- Registration Number
- NCT04545957
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBrigham and Women Hospital, Boston, Massachusetts, United States
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 1500
- Registration Number
- NCT04541654
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธBoston Children's Hospital, Boston, Massachusetts, United States
๐บ๐ธJudy E. Garber, Boston, Massachusetts, United States